trending Market Intelligence /marketintelligence/en/news-insights/trending/RtWAMOykdZsLabvX2fGSGQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Moody's places Mallinckrodt ratings on review after Sucampo deal

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Moody's places Mallinckrodt ratings on review after Sucampo deal

Moody's placed the ratings of Mallinckrodt International Finance SA, including the Ba3 corporate family rating and Ba3-PD probability of default rating, under review for downgrade.

The rating agency also affirmed the SGL-2 speculative grade liquidity rating.

In 2014, Moody's transferred Mallinckrodt Plc's ratings to the entity Mallinckrodt International Finance SA due to administrative reasons

The ratings action comes on heels of the company's announcement that it will buy Sucampo Pharmaceuticals Inc. for about $1.2 billion.

Moody's said the acquisition increases Mallinckrodt's gross debt/EBITDA to around 4.9x on a pro forma basis from around 4.4x and reduces its financial flexibility. Mallinckrodt also faces earnings pressure in its specialty generics segment and sales growth headwinds in 2018 on its largest drug, Acthar.

However, the agency believes the deal provides incremental earnings diversification for a few years and improves the company's pipeline of late stage drugs.

The rating agency's review will focus on the earnings outlook and pipeline of Sucampo, Mallinckrodt's deleveraging timeline and capabilities, and the mix of funding sources.

Mallinckrodt's existing Ba3 corporate family rating is supported by the company's moderate scale in specialty branded pharmaceuticals, good free cash flow and healthy liquidity. The rating is constrained by the company's high concentration of profits in one product, Acthar, and in controlled substances.

Acthar accounts for 40% of sales and a greater share of profits. The drug is not protected by any patents; however, companies would face significant obstacles to get a generic copy approved.

Moody's said the ratings are also constrained by Mallinckrodt's "aggressive appetite" for acquisitions that will likely lead to increased leverage from time to time.